NRG1 Expression

CI-VAR-00001035Explore in graph →CIViC 314

Curated evidence

Evidence by cancer (9 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–9 of 9 evidence items across 6 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Head and Neck Squamous Cell Carcinoma1
NRG1 Expression	Lapatinib	Predictive	D	Supports Sensitivity Response	4	accepted	EID776 In non-HER2 amplified cell lines, sensitivity to HER2 kinase inhibitor lapatinib was found mainly in cell-lines with elevated NRG1 expression and HER3 activation. This aberration was mainly identified… (full text at CIViC) PMID 21840482 · Wilson et al., 2011 · Open in CIViC	civic
Lung Non-Small Cell Carcinoma4
NRG1 Expression	Afatinib	Predictive	C	Supports Sensitivity Response	2	submitted	EID7653 In this study, an NRG1 overexpressing PC9HRG cell line was resistant to erlotinib because of active HER3 signalling. Treatment with afatinib was effective in disrupting signaling and cell line viabili… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Breast Neoplasm1
NRG1 Expression	Lapatinib	Predictive	D	Supports Resistance	3	submitted	EID1967 Reactivation of EGFR, HER2 and HER3 occurred within 24 hours of lapatinib treatment in breast cancer cell lines, This was associated with increased expression of NRG1 in cells treated with lapatinib. PMID 25691057 · Leung et al., 2015 · Open in CIViC	civic

Malignant Colorectal Neoplasm1
NRG1 Expression	Cetuximab	Predictive	D	Supports Resistance	4	accepted	EID777 NRG1 upregulation or ERBB2 amplification were the main causes of resistance to cetuximab in-vivo and in-vitro in this study. Inhibition of ERBB2/ERBB3 signaling restored cetuximab sensitivity. PMID 21900593 · Yonesaka et al., 2011 · Open in CIViC	civic

Malignant Neoplasm1
NRG1 Expression	Anti-ErbB3 Monoclonal Antibody AV-203	Predictive	D	Supports Sensitivity Response	3	accepted	EID861 This screening study in various tumor xenografts identified NRG1 expression to correlate with sensivity to ERBB3 inhibitory antibody AV-203. ERBB3 expression was not predictive of response. PMID 25542901 · Meetze et al., 2015 · Open in CIViC	civic

Malignant Ovarian Neoplasm1
NRG1 Expression	Seribantumab	Predictive	D	Supports Sensitivity Response	3	accepted	EID778 An NRG1-ERBB3 autocrine signal-transducing loop was identified in a subset of ovarian cancers and cell lines. Disruption of this loop led to decreased cell-growth in-vitro and prolonged survival in-vi… (full text at CIViC) PMID 20227043 · Sheng et al., 2010 · Open in CIViC	civic